Collegium Pharmaceutical, Inc. · NASDAQ:COLL
Collegium Pharmaceutical — Investor Presentation (January 2025)
41 slides from Collegium Pharmaceutical's investor presentation, Jan 8, 2025
Slide 1: Investor Presentation January 2025
Investor Presentation January 2025 | Nasdaq: COLL Healthier people. Stronger communities.
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipat
Slide 3: Building a Leading, Diversified Biopharmaceutical Company
Building a Leading, Diversified Biopharmaceutical Company
Slide 4: Successful Track Record in Building a Leading, Diversified Biopharmaceutical Company
4 Successful Track Record in Building a Leading, Diversified Biopharmaceutical Company Strong Commercial Execution Strategic Capital Deployment Robust Financial Results Adjusted EBITDA 4 $197 M Share repurchases conducted since inception 6 $1.6 B Invested in business development to date 5 Product Re
Slide 5: Next Phase of Growth – Building on a Successful Strategy
DRIVE SIGNIFICANT Jornay PM ® Growth • Invest in Jornay PM to support near - term growth and create significant momentum in 2026 and beyond • Raise awareness in patients and caregivers to drive prescription growth • Expand commercial presence in neuropsychiatry 5 Next Phase of Growth – Building on a
Slide 6: 2025 Financial Guidance Reflects Strong Top- and Bottom-Line Growth
2025 Financial Guidance Reflects Strong Top - and Bottom - Line Growth 1. Represents a n on - GAAP financial measure. Refer to “Non - GAAP Financial Measures” on slide 2. 2. This financial data was provided by Collegium in its press release filed with the SEC on January 8, 2025. 3. This financial da
Slide 7: Expanding into Neuropsychiatry with Jornay PM
Expanding into Neuropsychiatry with Jornay PM
Slide 8: Expansion into Neuropsychiatry Offers Opportunity in Large and Growing ADHD Market
8 Expansion into Neuropsychiatry Offers Compelling Opportunity in Large and Growing Attention Deficit Hyperactivity Disorder (ADHD) Market Growing Total ADHD Prescriptions 3 ADHD Prevalence 1 ~6.5M Pediatric and Adolescents ~15.5M Adults ~20K HCPs writing 1/3 of long - acting stimulant prescriptions
Slide 9: Highly Differentiated Product in the ADHD Market
9 Highly Differentiated Product in the ADHD Market • Highly differentiated central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD in people six years of age and older in the U.S. • Only stimulant ADHD medication with convenient evening dosing , and predictable onset u
Slide 10: Jornay PM Generated Significant Growth in 2024
11,400 14,100 July 2024 November 2024 10 Jornay PM Generated Significant Growth in 2024 Marked by an Acceleration Under Collegium’s Ownership STRONG AND GROWING PRESCRIBER BASE 2 ACCELERATION IN AVERAGE WEEKLY PRESCRIPTIONS DURING “BACK - TO - SCHOOL” SEASON 3 15.7K 17.0K 18.1K 19.3K 20.7K 21.4K 22.
Slide 11: Jornay PM: Strong Brand Fundamentals from HCP's Perspective
Jornay PM Recognized for Symptom Control by HCPS: 11 Jornay PM: Strong Brand Fundamentals from HCP’s Perspective 1 1. ADHD Long - Acting Stimulant Market ATU2 Q4, 2023. Jornay PM Considered Highly Favorable and Patient/Caregiver Requests Influence Prescribing # 1 recognized branded ADHD medication f
Slide 12: Investing in Jornay PM to Drive Revenue Growth
12 Investing in Jornay PM to Drive Revenue Growth Increase Awareness and Adoption with Expanded Set of Prescribers • Expand and optimize salesforce to cover full market opportunity • Leverage non - personal promotion to increase awareness and use of Jornay PM Raise Caregiver and Patient Awareness to
Slide 13: The Leader in Responsible Pain Management
The Leader in Responsible Pain Management
Slide 14: Well Positioned to Maximize and Enhance Durability of Pain Portfolio
14 Well Positioned to Maximize and Enhance Durability of Pain Portfolio $103.7M $138.8M $177.4M 2021 2022 2023 $128.9M $139.9M 3Q23 YTD 3Q24 YTD +9% $148.2M 1 $153.0M 2 $182.1M 2021 2022 2023 $132.8M $156.1M 3Q23 YTD 3Q24 YTD +18% +3% +19% +34% +28% 1. This financial data was provided by BioDelivery
Slide 15: Nucynta Franchise: Robust Revenue Contributor in 2025 and Beyond
$173.2M $184.5M $190.8M 2021 2022 2023 Product Revenues, Net Nucynta Franchise net revenue All other net product revenue 15 Nucynta Franchise: Robust Revenue Contributor in 2025 and Beyond Durable Revenue Contributor Improved Outlook for 2025 and Beyond Recent Grünenthal Settlement with Teva results
Slide 16: Strong Track Record of Execution and Delivering on Financial Commitments
Strong Track Record of Execution and Delivering on Financial Commitments
Slide 17: Track Record of Strong Top- and Bottom-Line Growth
17 Track Record of Strong Top - and Bottom - Line Growth GROW LEVERAGE EXPAND 1. This financial data was provided by Collegium in its Annual Report on Form 10 - K filed with the SEC on February 23, 2023. 2. This financial data was provided by Collegium in its Annual Report on Form 10 - K filed with
Slide 18: Robust Operating Cash Flow Generation from Pain Portfolio
$120M 3Q24 YTD p 18 Robust Operating Cash Flow Generation from Pain Portfolio 2019 Through Third Quarter 2024 1. This financial data was provided by Collegium in its Annual Reports on Form 10 - K filed with the SEC on February 25, 2021; Feb ruary 24, 2022; February 23, 2023; and February 22, 2024, a
Slide 19: Disciplined Capital Deployment
Disciplined Capital Deployment
Slide 20: Track Record of Successful Business Development Drives Growth
$104M $139M $177M $173M $325M $390M 2021 2022 2023 2024E 2025E 20 Track Record of Successful Business Development Drives Top - and Bottom - Line Growth 1. Represents the sum of the purchase price consideration paid for the Nucynta Acquisition in 2020, the BDSI Acquisition in 2 022 , and the upfront
Slide 21: Opportunistic Share Repurchases Deliver Value to Shareholders
2021 2022 2023 2024 YTD ASR program Open market share repurchases 21 Opportunistic Share Repurchases Deliver Value to Shareholders 1 1. This financial data is calculated from data provided by Collegium in its Form 8 - K filed with the SEC on January 8, 2025, Form 10 - Q filed with the SEC on Novembe
Slide 22: Balance Sheet Strength and Flexibility Driven by Disciplined Debt Management
22 Balance Sheet Strength and Flexibility Driven by Disciplined Debt Management 1. Represents period en d figures. This financial data was provided by Collegium on Form 10 - K filed with the SEC on February 24, 2022, February 23, 2023 , and February 22, 2024. 2024 estimates are based on scheduled de
Slide 23: Strong IP Management
Strong IP Management
Slide 24: Patent Protected Commercial Portfolio
24 Patent Protected Commercial Portfolio Reflects ( i ) for Xtampza ER, the September 2033 entry date set forth in Collegium’s settlement agreement with Teva; (ii) for Belbuca , the January 2027 entry date set forth in BDSI’s settlement agreement with Teva; (iii) for Jornay PM, which does not have a
Slide 25: Summary
Summary
Slide 26: 2025 and Beyond: Jornay PM Leading Collegium's Next Phase of Growth
2025 and Beyond: Jornay PM Leading Collegium’s Next Phase of Growth 26 Creating value for shareholders by: Growing revenue Increasing profitability Generating strong cash flows Strategically deploying capital STRATEGICALLY Deploy capital in a disciplined manner: • Expand commercial portfolio through
Slide 27: Important Safety Information
Important Safety Information
Slide 28: Important Safety Information about Jornay PM
28 Important Safety Information about Jornay PM (methylphenidate HCI extended - release capsules) WARNING: ABUSE, MISUSE, AND ADDICTION JORNAY PM has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including ad diction. Misuse and abuse of CNS st
Slide 29: Important Safety Information about Jornay PM: Warnings and Precautions
29 Important Safety Information about Jornay PM (methylphenidate HCI extended - release capsules) WARNINGS AND PRECAUTIONS JORNAY PM can cause serious adverse reactions and patients should be monitored for the following: Risks to Patients with Serious Cardiac Disease: Sudden death has been reported
Slide 30: Important Safety Information about XTAMPZA ER
30 Important Safety Information about XTAMPZA ER (oxycodone) extended - release capsules WARNING: SERIOUS AND LIFE - THREATENING RISKS FROM USE OF XTAMPZA ER Addiction, Abuse, and Misuse Because the use of XTAMPZA ER exposes patients and other users to the risks of opioid addiction, abuse, and misus
Slide 31: Important Safety Information about XTAMPZA ER: REMS
31 Important Safety Information about XTAMPZA ER (oxycodone) extended - release capsules Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) Healthcare providers are strongly encouraged to complete a REMS - compliant education program and to counsel patients and caregive rs on serious ri
Slide 32: Important Safety Information about BELBUCA
32 Important Safety Information about BELBUCA (buprenorphine buccal film) WARNING: SERIOUS AND LIFE - THREATENING RISKS FROM USE OF BELBUCA Addiction, Abuse, and Misuse BELBUCA exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and dea th
Slide 33: Important Safety Information about NUCYNTA ER
33 Important Safety Information about NUCYNTA ER (tapentadol) extended - release tablets WARNING: SERIOUS AND LIFE - THREATENING RISKS FROM USE OF NUCYNTA ER Addiction, Abuse, and Misuse Because the use of NUCYNTA ER exposes patients and other users to the risks of opioid addiction, abuse, and misus
Slide 34: Important Safety Information about NUCYNTA ER: Neonatal Opioid Withdrawal Syndrome
34 Important Safety Information about NUCYNTA ER (tapentadol) extended - release tablets Neonatal Opioid Withdrawal Syndrome If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which m ay be life - threatening if not recognized and tr
Slide 35: Important Safety Information about NUCYNTA Tablets
35 Important Safety Information about NUCYNTA (Tapentadol) tablets WARNING: SERIOUS AND LIFE - THREATENING RISKS FROM USE OF NUCYNTA TABLETS Addiction, Abuse, and Misuse Because the use of NUCYNTA tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, whic h c
Slide 36: Important Safety Information about SYMPROIC
36 Important Safety Information about SYMPROIC (naldemedine) tablets SYMPROIC may cause serious side effects, including: – Tear in your stomach or intestinal wall (perforation). Stomach pain that is severe can be a sign of a serious medical conditi on. If you get stomach pain that does not go away,
Slide 37: Important Safety Information about SYMPROIC: Indications and Usage
37 Important Safety Information about SYMPROIC ( naldemedine ) tablets INDICATIONS AND USAGE SYMPROIC is indicated for the treatment of opioid - induced constipation (OIC) in adult patients with chronic non - cancer pain, inc luding patients with chronic pain related to prior cancer or its treatment
Slide 38: Important Safety Information about SYMPROIC: Use in Specific Populations
38 Important Safety Information about SYMPROIC ( naldemedine ) tablets USE IN SPECIFIC POPULATIONS Pregnancy : There are no available data with Naldemedine in pregnant women to inform a drug - associated risk of major birth defects and miscarriage . There is a potential for opioid withdrawal in a fe
Slide 39: Non-GAAP Reconciliations
Non - GAAP Reconciliations
Slide 40: Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA
40 Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA (in thousands , unaudited) GAAP net income (loss) $ 9,335 $ 20,634 $ 48,155 $ (25,002) $ 71,517 Adjustments: Interest expense 18,394 20,768 83,339 63,213 21,014 Interest income (3,280) (4,538) (15,615) (1,047) (12) Loss on extinguishment
Slide 41: Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses
41 Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses (in thousands, unaudited) GAAP operating expenses $ 61,955 $ 35,298 $ 159,208 $ 176,169 $ 132,989 Adjustments: Stock-based compensation 7,317 7,027 27,136 22,874 24,255 Restructuring — — — — 4,578 Litigation settlements — —
Collegium Pharmaceutical — Investor Presentation (January 2025) on 6ix